Department of Nephrology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow 226014, India.
Apollo Medics Kanpur Road, Lucknow 226012, India.
Nutrients. 2022 Aug 12;14(16):3302. doi: 10.3390/nu14163302.
Hyperphosphatemia has emerged as an independent risk factor for cardiovascular disease (CVD) and excess mortality in chronic kidney disease (CKD). The study evaluates the effect of dietary phosphorus (Ph) restriction (DPhR) at an early stage as a therapeutic strategy for delaying CKD progression and preventing CVD. Methods: This was a one-year interventional study conducted on 79 stage 1 and 2 CKD patients. The dietary phosphorus intake (DPhI), fibroblast growth factor-23 (FGF-23), sKlotho and serum phosphorous (SP) levels were analyzed. Patients were categorized into two groups based on their DPhI, recommended DPhI (RPhI) with <1000 mg/day of dietary phosphorous (dietary counselling) and high DPhI (HPhI) with >1000 mg/day (dietary intervention). For comparisons of differences between the two groups, independent t-test; for correlation analysis, Pearson correlation; for identifying the significant associated risk factors for CKD, binary logistic regression analysis and for comparing the means across the three visits, repeated measures ANOVA were used for statistical analysis. Results: The mean age and glomerular filtration rate (GFR) of CKD patients were 38 ± 12 years and 82.95 ± 16.93 mL/min/1.73 m2. FGF-23, SP, dietary protein and DPhI were significantly higher and sKlotho was significantly lower in HPhI group than RPhI group. In HPhI group; GFR, sKlotho, SP and FGF-23 correlated significantly with DPhI. Risk factors with a statistical bearing on the progression of CKD were animal-based diet, family history of CKD and hypertension. In HPhI group; GFR, DPhI, SP and FGF-23 levels significantly improved within the intervention period whereas a significant increase in sKlotho levels was observed in both the groups. Conclusion: Restricting DPhI emerged as a favorable therapeutic strategy for CKD patients for improving renal function and controlling hyperphosphatemia. The results of the present study may serve as the basis for future interventional studies with dietary phosphate restriction in the initial stages of CKD that would preserve renal function. Highlights: Early restriction of dietary phosphorus prevents decline in eGFR, elevation in FGF23 and increases Klotho levels.
高磷血症已成为慢性肾脏病(CKD)患者心血管疾病(CVD)和死亡的独立危险因素。本研究旨在评估早期饮食磷限制(DPhR)作为延缓 CKD 进展和预防 CVD 的治疗策略的效果。
这是一项为期一年的干预性研究,共纳入 79 名 1 期和 2 期 CKD 患者。分析饮食磷摄入(DPhI)、成纤维细胞生长因子 23(FGF-23)、Klotho 和血清磷(SP)水平。根据 DPhI 将患者分为两组,推荐 DPhI(RPhI)<1000mg/天的饮食磷(饮食咨询)和高 DPhI(HPhI)>1000mg/天(饮食干预)。采用独立 t 检验比较两组间差异,Pearson 相关分析比较相关性,二元逻辑回归分析确定 CKD 的显著相关危险因素,重复测量方差分析比较三次就诊时的均值。
CKD 患者的平均年龄和肾小球滤过率(GFR)分别为 38±12 岁和 82.95±16.93ml/min/1.73m2。HPhI 组的 FGF-23、SP、饮食蛋白和 DPhI 明显高于 RPhI 组,sKlotho 明显低于 RPhI 组。在 HPhI 组,GFR、sKlotho、SP 和 FGF-23 与 DPhI 显著相关。与 CKD 进展有统计学意义的危险因素是动物源性饮食、CKD 家族史和高血压。在 HPhI 组,干预期间 GFR、DPhI、SP 和 FGF-23 水平显著改善,两组 sKlotho 水平均显著升高。
限制 DPhI 是改善 CKD 患者肾功能和控制高磷血症的有利治疗策略。本研究结果可为 CKD 早期饮食磷酸盐限制的干预研究提供依据,以保护肾功能。
早期限制饮食磷可防止 eGFR 下降、FGF23 升高和 Klotho 水平升高。